vs

Side-by-side financial comparison of Entergy (ETR) and Labcorp (LH). Click either name above to swap in a different company.

Labcorp is the larger business by last-quarter revenue ($3.5B vs $3.0B, roughly 1.2× Entergy). Entergy runs the higher net margin — 8.1% vs 4.7%, a 3.4% gap on every dollar of revenue. On growth, Entergy posted the faster year-over-year revenue change (7.9% vs 5.6%). Labcorp produced more free cash flow last quarter ($490.3M vs $-909.7M). Over the past eight quarters, Labcorp's revenue compounded faster (5.2% CAGR vs 2.9%).

Entergy Corporation is an American energy company engaged in electric power production and retail distribution operations in the Deep South of the United States. Entergy is headquartered in New Orleans, Louisiana, and generates and distributes electric power to three million customers in Arkansas, Louisiana, Mississippi and Texas. Entergy has approximately 24,000 megawatts of electric generating capacity, annual revenues of $11 billion and employs more than 12,000 people.

Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.

ETR vs LH — Head-to-Head

Bigger by revenue
LH
LH
1.2× larger
LH
$3.5B
$3.0B
ETR
Growing faster (revenue YoY)
ETR
ETR
+2.3% gap
ETR
7.9%
5.6%
LH
Higher net margin
ETR
ETR
3.4% more per $
ETR
8.1%
4.7%
LH
More free cash flow
LH
LH
$1.4B more FCF
LH
$490.3M
$-909.7M
ETR
Faster 2-yr revenue CAGR
LH
LH
Annualised
LH
5.2%
2.9%
ETR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ETR
ETR
LH
LH
Revenue
$3.0B
$3.5B
Net Profit
$240.5M
$164.7M
Gross Margin
28.2%
Operating Margin
18.4%
7.6%
Net Margin
8.1%
4.7%
Revenue YoY
7.9%
5.6%
Net Profit YoY
-16.2%
14.9%
EPS (diluted)
$0.51
$1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ETR
ETR
LH
LH
Q4 25
$3.0B
$3.5B
Q3 25
$3.8B
$3.6B
Q2 25
$3.3B
$3.5B
Q1 25
$2.8B
$3.3B
Q4 24
$2.7B
$3.3B
Q3 24
$3.4B
$3.3B
Q2 24
$3.0B
$3.2B
Q1 24
$2.8B
$3.2B
Net Profit
ETR
ETR
LH
LH
Q4 25
$240.5M
$164.7M
Q3 25
$698.4M
$261.1M
Q2 25
$472.0M
$237.9M
Q1 25
$362.4M
$212.8M
Q4 24
$287.2M
$143.4M
Q3 24
$645.8M
$169.3M
Q2 24
$51.7M
$205.3M
Q1 24
$76.5M
$228.0M
Gross Margin
ETR
ETR
LH
LH
Q4 25
28.2%
Q3 25
28.8%
Q2 25
29.7%
Q1 25
28.3%
Q4 24
26.9%
Q3 24
27.6%
Q2 24
28.8%
Q1 24
28.2%
Operating Margin
ETR
ETR
LH
LH
Q4 25
18.4%
7.6%
Q3 25
29.4%
11.1%
Q2 25
25.2%
11.2%
Q1 25
24.6%
9.7%
Q4 24
24.4%
6.5%
Q3 24
33.2%
7.7%
Q2 24
20.9%
9.2%
Q1 24
8.5%
10.1%
Net Margin
ETR
ETR
LH
LH
Q4 25
8.1%
4.7%
Q3 25
18.3%
7.3%
Q2 25
14.2%
6.7%
Q1 25
12.7%
6.4%
Q4 24
10.5%
4.3%
Q3 24
19.1%
5.2%
Q2 24
1.8%
6.4%
Q1 24
2.7%
7.2%
EPS (diluted)
ETR
ETR
LH
LH
Q4 25
$0.51
$1.98
Q3 25
$1.53
$3.12
Q2 25
$1.05
$2.84
Q1 25
$0.82
$2.52
Q4 24
$0.66
$1.72
Q3 24
$1.50
$2.00
Q2 24
$0.11
$2.43
Q1 24
$0.18
$2.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ETR
ETR
LH
LH
Cash + ST InvestmentsLiquidity on hand
$1.9B
$532.3M
Total DebtLower is stronger
$30.3B
Stockholders' EquityBook value
$16.9B
$8.6B
Total Assets
$71.9B
$18.4B
Debt / EquityLower = less leverage
1.79×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ETR
ETR
LH
LH
Q4 25
$1.9B
$532.3M
Q3 25
$1.5B
$598.1M
Q2 25
$1.2B
$647.3M
Q1 25
$1.5B
$369.4M
Q4 24
$859.7M
$1.5B
Q3 24
$1.4B
$1.5B
Q2 24
$1.4B
$265.1M
Q1 24
$1.3B
$99.3M
Total Debt
ETR
ETR
LH
LH
Q4 25
$30.3B
Q3 25
$29.0B
Q2 25
$29.9B
Q1 25
$29.6B
Q4 24
$28.0B
Q3 24
$27.9B
Q2 24
$27.8B
Q1 24
$26.5B
Stockholders' Equity
ETR
ETR
LH
LH
Q4 25
$16.9B
$8.6B
Q3 25
$16.7B
$8.7B
Q2 25
$16.2B
$8.5B
Q1 25
$15.2B
$8.3B
Q4 24
$15.1B
$8.1B
Q3 24
$15.0B
$8.2B
Q2 24
$14.6B
$8.0B
Q1 24
$14.5B
$8.0B
Total Assets
ETR
ETR
LH
LH
Q4 25
$71.9B
$18.4B
Q3 25
$69.8B
$18.3B
Q2 25
$68.4B
$18.1B
Q1 25
$66.6B
$17.6B
Q4 24
$64.8B
$18.4B
Q3 24
$64.5B
$18.6B
Q2 24
$62.8B
$16.7B
Q1 24
$61.6B
$16.5B
Debt / Equity
ETR
ETR
LH
LH
Q4 25
1.79×
Q3 25
1.74×
Q2 25
1.85×
Q1 25
1.95×
Q4 24
1.86×
Q3 24
1.85×
Q2 24
1.91×
Q1 24
1.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ETR
ETR
LH
LH
Operating Cash FlowLast quarter
$1.2B
$614.2M
Free Cash FlowOCF − Capex
$-909.7M
$490.3M
FCF MarginFCF / Revenue
-30.7%
13.9%
Capex IntensityCapex / Revenue
71.9%
3.5%
Cash ConversionOCF / Net Profit
5.06×
3.73×
TTM Free Cash FlowTrailing 4 quarters
$-2.5B
$1.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ETR
ETR
LH
LH
Q4 25
$1.2B
$614.2M
Q3 25
$2.1B
$387.2M
Q2 25
$1.3B
$620.6M
Q1 25
$536.2M
$18.5M
Q4 24
$1.4B
$777.2M
Q3 24
$1.6B
$277.3M
Q2 24
$1.0B
$561.1M
Q1 24
$521.1M
$-29.8M
Free Cash Flow
ETR
ETR
LH
LH
Q4 25
$-909.7M
$490.3M
Q3 25
$246.0M
$280.5M
Q2 25
$-746.6M
$542.7M
Q1 25
$-1.1B
$-107.5M
Q4 24
$-193.8M
$665.1M
Q3 24
$421.8M
$161.5M
Q2 24
$-137.8M
$432.9M
Q1 24
$-440.1M
$-163.6M
FCF Margin
ETR
ETR
LH
LH
Q4 25
-30.7%
13.9%
Q3 25
6.5%
7.9%
Q2 25
-22.4%
15.4%
Q1 25
-39.5%
-3.2%
Q4 24
-7.1%
20.0%
Q3 24
12.4%
4.9%
Q2 24
-4.7%
13.4%
Q1 24
-15.7%
-5.2%
Capex Intensity
ETR
ETR
LH
LH
Q4 25
71.9%
3.5%
Q3 25
49.5%
3.0%
Q2 25
60.3%
2.2%
Q1 25
58.3%
3.8%
Q4 24
57.4%
3.4%
Q3 24
33.7%
3.5%
Q2 24
39.4%
4.0%
Q1 24
34.4%
4.2%
Cash Conversion
ETR
ETR
LH
LH
Q4 25
5.06×
3.73×
Q3 25
3.06×
1.48×
Q2 25
2.67×
2.61×
Q1 25
1.48×
0.09×
Q4 24
4.80×
5.42×
Q3 24
2.42×
1.64×
Q2 24
19.82×
2.73×
Q1 24
6.81×
-0.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ETR
ETR

Electricity Us Regulated$2.9B100%
Other$13.7M0%

LH
LH

Diagnostics$2.7B78%
Biopharma Laboratory Services$793.0M23%

Related Comparisons